Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Aspirin Metformin
Bamlanivimab Molnupiravir
Bromhexine Nigella Sativa
Budesonide Nitazoxanide
Casirivimab/i.. Povidone-Iod..
Colchicine Probiotics
Conv. Plasma Proxalutamide
Curcumin Quercetin
Favipiravir Remdesivir
Fluvoxamine Sotrovimab
Hydroxychloro.. Vitamin A
Iota-carragee.. Vitamin C
Ivermectin Vitamin D
Melatonin Zinc

Other Adoption
Ivermectin study #119 of 124   Meta Analysis
9/6 Early treatment study
Buonfrate et al., SSRN, doi:10.2139/ssrn.3918289 (Preprint)
High Dose Ivermectin for the Early Treatment of COVID-19 (COVIER Study): A Randomised, Double-Blind, Multicentre, Phase II, Dose-Finding, Proof of Concept Clinical Trial
Source   PDF   Share   Tweet
Early terminated 89 patient RCT with 29 high dose and 32 very high dose ivermectin patients, showing dose dependent viral load reduction, although not reaching statistical significance due to early termination. Since most patients have low viral load at day 7, there is little room for improvement with a treatment at day 7. Intermediate results may show significantly greater improvement, but are not provided. Authors note that ivermectin remained safe even at the very high dose used, although tolerability was reduced. 3 patients were hospitalized in the very high dose ivermectin arm (and 1 in the high dose arm) versus 0 in the control arm. While this result is not statistically significant, it may be in part due to randomization failure because 9 patients were randomized at the hospital for very high dose ivermectin versus 4 in the control arm, suggesting higher baseline severity. Supplementary data is not currently available. COVIER. NCT04438850.
Buonfrate et al., 9/6/2021, Double Blind Randomized Controlled Trial, Italy, Europe, preprint, 18 authors, dosage 1200μg/kg days 1-5, arm B 600µg/kg, arm C 1200µg/kg.
risk of hospitalization, 600.0% higher, RR 7.00, p = 0.30, treatment 4 of 58 (6.9%), control 0 of 29 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm).
relative change in viral load, RR 0.69, p = 0.10, treatment 30, control 29, day 7, arm C.
relative change in viral load, RR 0.86, p = 0.12, treatment 28, control 29, day 7, arm B.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
All 124 studies   Meta Analysis
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Submit